De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Trans Recip
Status:
Recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
CMV viremia will be treated with either oral valganciclovir, intravenous ganciclovir or
alternative agents, according to AST ID COP (American Society of Transplantation Infectious
disease community of practice) guidelines.